466
Background:
Treatment-related adverse events (TRAEs) are a common cause of discontinuation in cancer clinical trials. Although TRAEs are routinely documented, the relative contributions of patients (pts), clinicians, and protocol-mandated requirements to these decisions remain poorly characterized. We sough...
Hannah Pearl, Breanna Yi-Zhu Yang, Jacob Abrahams et al.· JCO Oncology Practice· 0 citations
Barriers to EPCT participation among a group of minoritized trial participants and caregivers were driven by a combination of limited awareness, language barriers, logistical intensity, fear of uncertainty, and historical distrust.
I. Yao, Marina Serrano Fernandez, Taira Anderson et al.· JCO Oncology Practice· 0 citations
118
Background:
Black and Hispanic patients remain underrepresented in early-phase cancer clinical trials (EPCTs), limiting equitable access to novel therapies. Building on a pilot study of a community navigator (CN)-led intervention that was feasible, acceptable, and had positive stakeholder feedback, we condu...
Marina Serrano Fernandez, I. Yao, Taira Anderson et al.· JCO Oncology Practice· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.